AIMS: Withdrawal symptoms have been linked to a propensity for relapse to drug abuse. Inasmuch as this association applies to methamphetamine (MA) abuse, an understanding of the course of MA withdrawal symptoms may help to direct treatment for MA dependence. Previous studies of symptoms manifested during abstinence from MA have been limited in size and scope. We asked (i) whether debilitating psychological and/or physical symptoms appear during the first several weeks of MA abstinence, (ii) how craving for MA evolves and (iii) whether psychiatric symptoms (e.g. depression, psychosis) persist beyond a month of abstinence. DESIGN: A study of MA-dependent participants, who initiated and maintained abstinence from the drug for up to 5 weeks, compared to a matched healthy comparison group. SETTING: In-patient research hospital ward (MA-dependent subjects) and out-patient (comparison subjects). PARTICIPANTS: Fifty-six MA-dependent and eighty-nine comparison subjects. MEASUREMENTS: Rater-assessed MA withdrawal questionnaire and self-report assessment of craving (MA-dependent subjects) and self-report assessment of psychiatric symptoms (both groups). FINDINGS: At study entry, MA-dependent subjects exhibited a wide range in severity of depressive symptoms, with the average score at a mild-moderate level of severity. Symptoms of psychosis were also prevalent. While depressive and psychotic symptoms largely resolved within a week of abstinence, craving did not decrease significantly from the time of initiating abstinence until the second week, and then continued at a reduced level to the fifth week. CONCLUSIONS: Depressive and psychotic symptoms accompany acute withdrawal from methamphetamine but resolve within 1 week. Craving is also present and lasts at least 5 weeks.
AIMS: Withdrawal symptoms have been linked to a propensity for relapse to drug abuse. Inasmuch as this association applies to methamphetamine (MA) abuse, an understanding of the course of MA withdrawal symptoms may help to direct treatment for MA dependence. Previous studies of symptoms manifested during abstinence from MA have been limited in size and scope. We asked (i) whether debilitating psychological and/or physical symptoms appear during the first several weeks of MA abstinence, (ii) how craving for MA evolves and (iii) whether psychiatric symptoms (e.g. depression, psychosis) persist beyond a month of abstinence. DESIGN: A study of MA-dependent participants, who initiated and maintained abstinence from the drug for up to 5 weeks, compared to a matched healthy comparison group. SETTING: In-patient research hospital ward (MA-dependent subjects) and out-patient (comparison subjects). PARTICIPANTS: Fifty-six MA-dependent and eighty-nine comparison subjects. MEASUREMENTS: Rater-assessed MA withdrawal questionnaire and self-report assessment of craving (MA-dependent subjects) and self-report assessment of psychiatric symptoms (both groups). FINDINGS: At study entry, MA-dependent subjects exhibited a wide range in severity of depressive symptoms, with the average score at a mild-moderate level of severity. Symptoms of psychosis were also prevalent. While depressive and psychotic symptoms largely resolved within a week of abstinence, craving did not decrease significantly from the time of initiating abstinence until the second week, and then continued at a reduced level to the fifth week. CONCLUSIONS:Depressive and psychotic symptoms accompany acute withdrawal from methamphetamine but resolve within 1 week. Craving is also present and lasts at least 5 weeks.
Authors: Buyean Lee; Edythe D London; Russell A Poldrack; Judah Farahi; Angelo Nacca; John R Monterosso; Jeanette A Mumford; Andrew V Bokarius; Magnus Dahlbom; Jogeshwar Mukherjee; Robert M Bilder; Arthur L Brody; Mark A Mandelkern Journal: J Neurosci Date: 2009-11-25 Impact factor: 6.167
Authors: Millie Rincón-Cortés; Kimberly G Gagnon; Hannah K Dollish; Anthony A Grace Journal: Neuropsychopharmacology Date: 2018-06-18 Impact factor: 7.853
Authors: Richard A Rawson; Joy Chudzynski; Rachel Gonzales; Larissa Mooney; Daniel Dickerson; Alfonso Ang; Brett Dolezal; Christopher B Cooper Journal: J Subst Abuse Treat Date: 2015-04-15
Authors: Angelica M Morales; Buyean Lee; Gerhard Hellemann; Joseph O'Neill; Edythe D London Journal: Drug Alcohol Depend Date: 2012-03-22 Impact factor: 4.492
Authors: Milky Kohno; Laura E Dennis; Holly McCready; Daniel L Schwartz; William F Hoffman; P Todd Korthuis Journal: Drug Alcohol Depend Date: 2018-09-21 Impact factor: 4.492
Authors: David Bosanquet; Hamish G Macdougall; Stephen J Rogers; Graham A Starmer; Rebecca McKetin; Alexander Blaszczynski; Iain S McGregor Journal: Psychopharmacology (Berl) Date: 2012-07-29 Impact factor: 4.530